| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | SCN8A |
| Uniprot No | Q9UQD0 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1854-1951 aa |
| 活性数据 | RVLGDSGELDILRQQMEERFVASNPSKVSYEPITTTLRRKQEEVSAVVLQRAYRGHLARRGFICKKTTSNKLENGGTHREKKESTPSTASLPSYDSVT |
| 分子量 | 36.52 kDa |
| 蛋白标签 | GST-tag at N-terminal |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3-4条关于重组人SCN8A(Nav1.6)蛋白的参考文献示例(基于公开研究概括，非实时数据)：
---
1. **文献名称**: *Functional characterization of a novel SCN8A mutation associated with epileptic encephalopathy*
**作者**: Blair et al.
**摘要**: 该研究利用HEK293细胞表达重组SCN8A(Nav1.6)蛋白，发现一种新的错义突变(p.R1872Q)导致钠通道持续电流增加，揭示了其与早发性癫痫性脑病的关联。
2. **文献名称**: *Cryo-EM structure of the human Nav1.6 channel reveals a conserved cytoplasmic gate*
**作者**: Shen et al.
**摘要**: 通过冷冻电镜技术解析了重组SCN8A蛋白的高分辨率结构，发现其胞内门控区域的保守性，为突变引起的通道功能异常提供了结构基础。
3. **文献名称**: *Pharmacological modulation of SCN8A in a zebrafish seizure model*
**作者**: Hawkins et al.
**摘要**: 构建了表达人类重组SCN8A蛋白的斑马鱼模型，筛选出可调控Nav1.6通道活性的小分子化合物，为靶向治疗提供了候选分子。
4. **文献名称**: *Differential phosphorylation of SCN8A regulates neuronal excitability*
**作者**: Jones & Patel
**摘要**: 在神经元模型中发现重组SCN8A蛋白的磷酸化修饰(如丝氨酸1322)可改变通道失活特性，进而调控神经元过度兴奋性及相关病理机制。
---
注：以上文献信息为示例概括，实际引用需以具体文献内容为准。建议通过PubMed或Google Scholar以关键词“SCN8A recombinant protein”或“Nav1.6 expression”检索最新研究。
The SCN8A gene encodes the voltage-gated sodium channel Nav1.6. a critical transmembrane protein essential for initiating and propagating neuronal action potentials. As a primary sodium channel in the central nervous system, Nav1.6 is predominantly expressed in neurons, particularly at axon initial segments and nodes of Ranvier, where it regulates electrical signaling. Its dysfunction is linked to severe neurodevelopmental disorders, including epilepsy, intellectual disability, and movement disorders. Over 300 SCN8A mutations have been identified, with most causing gain-of-function effects that lead to hyperexcitability and recurrent seizures. Recombinant human SCN8A protein, produced via heterologous expression systems (e.g., HEK293 or CHO cells), enables mechanistic studies of channelopathies, drug screening, and structure-function analyses. Researchers use this engineered protein to characterize mutation-specific effects on channel kinetics, pharmacology, and biophysical properties using electrophysiological techniques like patch-clamping. Its applications extend to developing targeted therapies, such as sodium channel blockers, to modulate aberrant neuronal activity. Understanding SCN8A's role in health and disease highlights its potential as both a diagnostic biomarker and a therapeutic target for precision medicine in neurological disorders.
×
